Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
J Theor Biol. 2011 Nov 7;288:9-20. doi: 10.1016/j.jtbi.2011.08.001. Epub 2011 Aug 10.
Vaginal microbicides (VMB) are currently among the few women-initiated biomedical interventions for preventing heterosexual transmission of HIV. In this paper we use a deterministic model of HIV transmission to assess the public-health benefits of a VMB intervention and evaluate its gender-specific impact over short (initial) and extended periods of time. We define two distinct quantitative benefit ratios (QBRs) based on infections prevented in men and women to create and study regions of male advantage in different parameter spaces. Our analysis exposes complicated temporal correlations between the QBRs and series of pre-intervention (e.g., HIV acquisition risks per act) and intervention parameters (e.g., VMB efficacy mechanisms, rates of resistance development and reversion) and indicates that different QBRs may often disagree on the gender distribution of the benefits from a VMB intervention. We also outline the strong influence of some modeling assumptions on the reported results and conclude that the assessment of VMB and other biomedical interventions must be based on more comprehensive analyses than calculations of infections prevented over a fixed period of time.
阴道杀微生物剂(VMB)是目前为数不多的女性主导的预防异性传播 HIV 的生物医学干预措施之一。在本文中,我们使用 HIV 传播的确定性模型来评估 VMB 干预措施的公共卫生效益,并在短(初始)和长(扩展)时间内评估其对特定性别的影响。我们定义了两个基于男性和女性预防感染的不同定量效益比(QBR),以在不同的参数空间中创建和研究男性优势区域。我们的分析揭示了 QBR 与一系列干预前参数(例如,每次行为的 HIV 感染风险)和干预参数(例如,VMB 疗效机制、耐药性发展和逆转率)之间复杂的时间相关性,并表明不同的 QBR 可能经常不同意 VMB 干预措施的效益在性别上的分配。我们还概述了一些建模假设对报告结果的强烈影响,并得出结论,必须基于更全面的分析来评估 VMB 和其他生物医学干预措施,而不仅仅是计算固定时间段内预防感染的数量。